BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33414519)

  • 1. AMOT suppresses tumor progression via regulating DNA damage response signaling in diffuse large B-cell lymphoma.
    Sang T; Yang J; Liu J; Han Y; Li Y; Zhou X; Wang X
    Cancer Gene Ther; 2021 Nov; 28(10-11):1125-1135. PubMed ID: 33414519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiomotin-p130 inhibits vasculogenic mimicry formation of small cell lung cancer independently of Smad2/3 signal pathway.
    Li D; Shen Y; Ren H; Wang L; Yang J; Wang Y
    J Bioenerg Biomembr; 2021 Jun; 53(3):295-305. PubMed ID: 33712992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B-cell lymphoma cells by targeting miR-497-5p/PIM1 axis.
    Zhu Q; Li Y; Guo Y; Hu L; Xiao Z; Liu X; Wang J; Xu Q; Tong X
    J Cell Mol Med; 2019 Nov; 23(11):7395-7405. PubMed ID: 31483572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing Aurora-kinase-A (AURKA) reinforced the sensitivity of diffuse large B-cell lymphoma cells to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) via suppressing β-Catenin and RAS-extracellular signal-regulated protein kinase (ERK1/2) pathway.
    Wang S; Sun L
    Bioengineered; 2021 Dec; 12(1):8296-8308. PubMed ID: 34565287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
    Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNA‑196a‑3p inhibits cell proliferation and promotes cell apoptosis by targeting ADP ribosylation factor 4 in diffuse large B‑cell lymphoma.
    Fu J; Lou X; Wan S; Zhao X; Chen Z; Zhu M; Guo L; Wu D; Wang S
    Oncol Rep; 2021 Feb; 45(2):764-775. PubMed ID: 33416178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma.
    Derenzini E; Agostinelli C; Imbrogno E; Iacobucci I; Casadei B; Brighenti E; Righi S; Fuligni F; Ghelli Luserna Di Rorà A; Ferrari A; Martinelli G; Pileri S; Zinzani PL
    Oncotarget; 2015 Mar; 6(9):6553-69. PubMed ID: 25544753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-645 regulates the proliferation and apoptosis of diffuse large B-cell lymphoma by targeting DACH1.
    Wang R; Shen J; Su N; Wang Q; Zhang M; Liu C
    Hum Cell; 2020 Oct; 33(4):1091-1098. PubMed ID: 32529465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. β-Elemene suppresses tumor growth of diffuse large B-cell lymphoma through regulating lncRNA HULC-mediated apoptotic pathway.
    Hu T; Gao Y
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32010942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma.
    Yang JM; Jang JY; Jeon YK; Paik JH
    J Transl Med; 2018 Jun; 16(1):162. PubMed ID: 29890998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR.
    Jin J; Wang L; Tao Z; Zhang J; Lv F; Cao J; Hu X
    Mol Med Rep; 2020 May; 21(5):2209-2219. PubMed ID: 32186759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LINC00857 contributes to proliferation and lymphomagenesis by regulating miR-370-3p/CBX3 axis in diffuse large B-cell lymphoma.
    Huang Y; Lin Y; Song X; Wu D
    Carcinogenesis; 2021 May; 42(5):733-741. PubMed ID: 33657224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. hsa‑miR‑429 targets CBX8 to promote cell apoptosis in diffuse large B‑cell lymphoma.
    Liang Y; Yu ZJ; Liu M; Liu HM; Zhang JZ; Xiong T; Tang YY; Huang ZP
    Mol Med Rep; 2021 Dec; 24(6):. PubMed ID: 34651663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma.
    Zhou X; Fang X; Jiang Y; Geng L; Li X; Li Y; Lu K; Li P; Lv X; Wang X
    J Hematol Oncol; 2017 Feb; 10(1):37. PubMed ID: 28153033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
    Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
    Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma.
    Uddin S; Hussain A; Ahmed M; Belgaumi A; Al-Dayel F; Ajarim D; Bavi P; Al-Kuraya KS
    J Pathol; 2008 Dec; 216(4):483-94. PubMed ID: 18850583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CircEAF2 counteracts Epstein-Barr virus-positive diffuse large B-cell lymphoma progression via miR-BART19-3p/APC/β-catenin axis.
    Zhao CX; Yan ZX; Wen JJ; Fu D; Xu PP; Wang L; Cheng S; Hu JD; Zhao WL
    Mol Cancer; 2021 Dec; 20(1):153. PubMed ID: 34852843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma.
    Wang X; Cao X; Sun R; Tang C; Tzankov A; Zhang J; Manyam GC; Xiao M; Miao Y; Jabbar K; Tan X; Pang Y; Visco C; Xie Y; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WWL; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Winter JN; Piris MA; Li S; Miranda RN; Medeiros LJ; Li Y; Xu-Monette ZY; Young KH
    Neoplasia; 2018 Jun; 20(6):574-593. PubMed ID: 29734016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.